# Official Journal C 194/30 J

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 194 |
| | |
| English edition | Information and Notices | Volume 4730 July 2004 |

ISSN 1725-2423

Official Journal

of the European Union

C 194

English edition

Information and Notices

Volume 4730 July 2004

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Commission |
| 2004/C 194/1 | Euro exchange rates | 1 |
| 2004/C 194/2 | Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June 2004 to 15 July 2004 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 | 2 |
| 2004/C 194/3 | Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 May 2004 to 15 June 2004 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) | 5 |
| 2004/C 194/4 | Ex post notification of Eurostat grants in 2003 — Public information | 6 |
| 2004/C 194/5 | Prior notification of a concentration (Case No COMP/M.3513 — CATERPILLAR/XPART) — Candidate case for simplified procedure (
  1
  ) | 7 |

Notice No

Contents

page

I   Information

Commission

2004/C 194/1

Euro exchange rates

1

2004/C 194/2

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June 2004 to 15 July 2004 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93

2

2004/C 194/3

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 May 2004 to 15 June 2004 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

5

2004/C 194/4

Ex post notification of Eurostat grants in 2003 — Public information

Ex post

6

2004/C 194/5

Prior notification of a concentration (Case No COMP/M.3513 — CATERPILLAR/XPART) — Candidate case for simplified procedure (
  1
  )

1

7

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

I Information

Commission

| 30.7.2004 | EN | Official Journal of the European Union | C 194/1 |
| --- | --- | --- | --- |

30.7.2004

EN

Official Journal of the European Union

C 194/1

---

Euro exchange rates (1)

29 July 2004

(2004/C 194/01)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2026 |
| JPY | Japanese yen | 135,00 |
| DKK | Danish krone | 7,4342 |
| GBP | Pound sterling | 0,66300 |
| SEK | Swedish krona | 9,2274 |
| CHF | Swiss franc | 1,5393 |
| ISK | Iceland króna | 86,45 |
| NOK | Norwegian krone | 8,4560 |
| BGN | Bulgarian lev | 1,9559 |
| CYP | Cyprus pound | 0,58020 |
| CZK | Czech koruna | 31,745 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 247,35 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6547 |
| MTL | Maltese lira | 0,4249 |
| PLN | Polish zloty | 4,3889 |
| ROL | Romanian leu | 41 134 |
| SIT | Slovenian tolar | 239,9800 |
| SKK | Slovak koruna | 40,120 |
| TRL | Turkish lira | 1 773 100 |
| AUD | Australian dollar | 1,7283 |
| CAD | Canadian dollar | 1,6028 |
| HKD | Hong Kong dollar | 9,3799 |
| NZD | New Zealand dollar | 1,9059 |
| SGD | Singapore dollar | 2,0774 |
| KRW | South Korean won | 1 405,87 |
| ZAR | South African rand | 7,5204 |

Currency

Exchange rate

USD

US dollar

1,2026

JPY

Japanese yen

135,00

DKK

Danish krone

7,4342

GBP

Pound sterling

0,66300

SEK

Swedish krona

9,2274

CHF

Swiss franc

1,5393

ISK

Iceland króna

86,45

NOK

Norwegian krone

8,4560

BGN

Bulgarian lev

1,9559

CYP

Cyprus pound

0,58020

CZK

Czech koruna

31,745

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

247,35

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6547

MTL

Maltese lira

0,4249

PLN

Polish zloty

4,3889

ROL

Romanian leu

41 134

SIT

Slovenian tolar

239,9800

SKK

Slovak koruna

40,120

TRL

Turkish lira

1 773 100

AUD

Australian dollar

1,7283

CAD

Canadian dollar

1,6028

HKD

Hong Kong dollar

9,3799

NZD

New Zealand dollar

1,9059

SGD

Singapore dollar

2,0774

KRW

South Korean won

1 405,87

ZAR

South African rand

7,5204

---

(1)

Source: reference exchange rate published by the ECB.

---

| 30.7.2004 | EN | Official Journal of the European Union | C 194/2 |
| --- | --- | --- | --- |

30.7.2004

EN

Official Journal of the European Union

C 194/2

---

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June 2004 to 15 July 2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1)

(2004/C 194/02)

—   Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 29.6.2004 | Erbitux | Merck KgaA |
| Frankfurter Straße 250 |
| D-64293 Darmstadt |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

29.6.2004

Erbitux

Merck KgaA

Frankfurter Straße 250

D-64293 Darmstadt

EU/1/04/281/001

1.7.2004

6.7.2004

Lyrica

| Pfizer Ltd |
| --- |
| Ramsgate Road |
| Sandwich |
| Kent CT13 9NJ |
| United Kingdom |

Pfizer Ltd

Ramsgate Road

Sandwich

Kent CT13 9NJ

United Kingdom

EU/1/04/279/001-025

8.7.2004

12.7.2004

Telzir

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/04/282/001-002

14.7.2004

—   Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 17.6.2004 | GONAL-f | Serono Europe Limited |
| 56, Marsh Wall |
| London E14 9TP |
| United Kingdom |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

17.6.2004

GONAL-f

Serono Europe Limited

56, Marsh Wall

London E14 9TP

United Kingdom

EU/1/95/001/005-008

EU/1/95/001/013-020

21.6.2004

17.6.2004

Beromun

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/99/097/001

21.6.2004

17.6.2004

Tractocile

| Ferring AB |
| --- |
| Soldattorpsvägen 5 |
| Box 30047 |
| S-200 61 Limhamn |

Ferring AB

Soldattorpsvägen 5

Box 30047

S-200 61 Limhamn

EU/1/99/124/001-002

21.6.2004

17.6.2004

Tritanrix HepB

| GlaxoSmithKline Biologicals sa |
| --- |
| Rue de l'Institut 89 |
| B-1330 Rixensart |

GlaxoSmithKline Biologicals sa

Rue de l'Institut 89

B-1330 Rixensart

EU/1/96/014/001-003

21.6.2004

23.6.2004

Emtriva

| Gilead Sciences International Limited |
| --- |
| Cambridge CB1 6GT |
| United Kingdom |

Gilead Sciences International Limited

Cambridge CB1 6GT

United Kingdom

EU/1/03/261/001-003

25.6.2004

23.6.2004

Kogenate Bayer

| Bayer AG |
| --- |
| D-51368 Leverkusen |

Bayer AG

D-51368 Leverkusen

EU/1/00/143/001-003

25.6.2004

24.6.2004

Helixate NexGen

| Bayer AG |
| --- |
| D-51368 Leverkusen |

Bayer AG

D-51368 Leverkusen

EU/1/00/144/001-003

28.6.2004

6.7.2004

Ammonaps

| Orphan Europe, Immeuble ‘Le Guillaumet’ |
| --- |
| F-92046 Paris-La Défense |

Orphan Europe, Immeuble ‘Le Guillaumet’

F-92046 Paris-La Défense

EU/1/99/120/001-004

8.7.2004

6.7.2004

Cialis

| Lilly ICOS Limited |
| --- |
| 25 New Street Square |
| London EC4A 3LN |
| United Kingdom |

Lilly ICOS Limited

25 New Street Square

London EC4A 3LN

United Kingdom

EU/1/02/237/001-004

8.7.2004

7.7.2004

Novomix 30

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/00/142/004-005

EU/1/00/142/007-010

12.7.2004

12.7.2004

Betaferon

| Schering AG Pharma |
| --- |
| D-13342 Berlin |

Schering AG Pharma

D-13342 Berlin

EU/1/95/003/001-004

14.7.2004

13.7.2004

Aldurazyme

| Genzyme Europe BV |
| --- |
| Gooimeer 10 |
| 1411 DD Naarden |
| Nederland |

Genzyme Europe BV

Gooimeer 10

1411 DD Naarden

Nederland

EU/1/03/253/001-003

15.7.2004

13.7.2004

Viramune

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/97/055/001-002

15.7.2004

13.7.2004

Avandamet

| SmithKline Beecham plc |
| --- |
| 980 Great West Road |
| Brentford |
| Middlesex TW8 9GS |
| United Kingdom |

SmithKline Beecham plc

980 Great West Road

Brentford

Middlesex TW8 9GS

United Kingdom

EU/1/03/258/001-006

15.7.2004

13.7.2004

Axura

| Merz Pharmaceuticals GmbH |
| --- |
| Eckenheimer Landstr. 100-104 |
| D-60318 Frankfurt/Main |

Merz Pharmaceuticals GmbH

Eckenheimer Landstr. 100-104

D-60318 Frankfurt/Main

EU/1/02/218/001-011

15.7.2004

13.7.2004

Optisulin

| Aventis Pharma Deutschland GmbH |
| --- |
| D-65926 Frankfurt am Main |

Aventis Pharma Deutschland GmbH

D-65926 Frankfurt am Main

EU/1/00/133/001-008

15.7.2004

13.7.2004

Aldara

| 3M Santé |
| --- |
| Boulevard de l'Oise |
| F-95029 Cergy Pontoise Cedex |

3M Santé

Boulevard de l'Oise

F-95029 Cergy Pontoise Cedex

EU/1/98/080/001

15.7.2004

13.7.2004

Sustiva

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| 141-149 Staines Road |
| Hounslow TW3 3JA |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

141-149 Staines Road

Hounslow TW3 3JA

United Kingdom

EU/1/99/110/001-009/

15.7.2004

13.7.2004

Lantus

| Aventis Pharma Deutschland GmbH |
| --- |
| D-65926 Frankfurt am Main |

Aventis Pharma Deutschland GmbH

D-65926 Frankfurt am Main

EU/1/00/134/001-021

15.7.2004

13.7.2004

Stocrin

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/99/111/001-009

15.7.2004

13.7.2004

Keppra

| UCB SA |
| --- |
| Allée de la recherche 60 |
| B-1070 Bruxelles / Researchdreef, 60 |
| B-1070 Brussel |

UCB SA

Allée de la recherche 60

B-1070 Bruxelles / Researchdreef, 60

B-1070 Brussel

EU/1/00/146/001-027

16.7.2004

13.7.2004

Zyprexa

| Eli Lilly Nederland BV |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland BV

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/96/022/002

EU/1/96/022/004

EU/1/96/022/006

EU/1/96/022/008-012

EU/1/96/022/014

EU/1/96/022/016-022

15.7.2004

13.7.2004

Ebixa

| H. Lundbeck A/S |
| --- |
| Ottiliavej 9 |
| DK-2500 Valby |

H. Lundbeck A/S

Ottiliavej 9

DK-2500 Valby

EU/1/02/219/001-013

15.7.2004

13.7.2004

Zyprexa Velotab

| Eli Lilly Nederland BV |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland BV

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/99/125/001-004

15.7.2004

—   Withdrawal of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 13.7.2004 | Taluvian | Abbott SpA |
| Campoverde di Aprilia |
| I-04010 Latina |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

13.7.2004

Taluvian

Abbott SpA

Campoverde di Aprilia

I-04010 Latina

EU/1/01/182/001-010

15.7.2004

---

(1)  OJ L 214, 24.8.1993, p. 1.

---

| 30.7.2004 | EN | Official Journal of the European Union | C 194/5 |
| --- | --- | --- | --- |

30.7.2004

EN

Official Journal of the European Union

C 194/5

---

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 May 2004 to 15 June 2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1))

(2004/C 194/03)

—   Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 4.6.2004 | Abilify | Otsuka Pharmaceutical Europe Ltd |
| Commonwealth House |
| 2 Chalkhill Road |
| Hammersmith |
| London W6 8DW |
| United Kingdom |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

4.6.2004

Abilify

Otsuka Pharmaceutical Europe Ltd

Commonwealth House

2 Chalkhill Road

Hammersmith

London W6 8DW

United Kingdom

EU/1/04/276/001-020

8.6.2004

---

(1)  OJ L 214, 24.8.1993, p. 1.

---

| 30.7.2004 | EN | Official Journal of the European Union | C 194/6 |
| --- | --- | --- | --- |

30.7.2004

EN

Official Journal of the European Union

C 194/6

---

EX POST NOTIFICATION OF EUROSTAT GRANTS IN 2003

Public information

(2004/C 194/04)

In accordance with Article 110(2) of the Financial Regulation and Article 169 of its implementing rules, the public is hereby informed of actions which benefited from a Eurostat grant in 2003.

The electronic file which covers the actions in question can be found on the EUROPA server (http://europa.eu.int). The file, which takes the form of a list, can be accessed by following the path ‘Institutions’, ‘Commission’, ‘Statistics’, ‘Eurostat Activities’ and ‘Calls for tenders and grants’, and then going into the file ‘Eurostat: List of grants awarded in 2003’.

The list indicates the file number, the unit responsible, the name and country of the beneficiaries, the title of the action, the amount granted and the co-financing rate of the action.

All of these actions were the subject of ex ante notification.

---

| 30.7.2004 | EN | Official Journal of the European Union | C 194/7 |
| --- | --- | --- | --- |

30.7.2004

EN

Official Journal of the European Union

C 194/7

---

Prior notification of a concentration

(Case No COMP/M.3513 — CATERPILLAR/XPART)

Candidate case for simplified procedure

(2004/C 194/05)

(Text with EEA relevance)

| 1. | On 20 July 2004 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Caterpillar Logistics Services (UK) Ltd (‘CAT’), belonging to the Caterpillar group, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the business of Xpart Ltd (‘Xpart’, UK), a subsidiary of Phoenix Venture Holdings, by way of purchase of assets. |
| --- | --- |

1.

On 20 July 2004 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Caterpillar Logistics Services (UK) Ltd (‘CAT’), belonging to the Caterpillar group, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the business of Xpart Ltd (‘Xpart’, UK), a subsidiary of Phoenix Venture Holdings, by way of purchase of assets.

| 2. | The business activities of the undertakings concerned are:






  — | CAT: logistics services, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

CAT: logistics services,

| — | Xpart: supply and distribution of parts for motor vehicles. |
| --- | --- |

—

Xpart: supply and distribution of parts for motor vehicles.

| 3. | On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3513 — Caterpillar/Xpart, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition, |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3513 — Caterpillar/Xpart, to the following address:

European Commission

Directorate-General for Competition,

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 217, 29.7.2000, p. 32; Council Regulation (EEC) No 4064/89 has been replaced by Council Regulation (EC) No 139/2004.

---